Januvia

India's top court rebuffs Merck, lets generic Januvia roll out

India's top court rebuffs Merck, lets generic Januvia roll out

Fierce Pharma

Johnson & Johnson's New Diabetes Drug And Its Competitors

Johnson & Johnson's New Diabetes Drug And Its Competitors

Seeking Alpha

Is Merck's Type 2 Diabetes Blockbuster in Trouble?

Is Merck's Type 2 Diabetes Blockbuster in Trouble?

Motley Fool

Diabetes Drugs Are Being Evaluated for Pancreatic Risk

Diabetes Drugs Are Being Evaluated for Pancreatic Risk

Bloomberg

Merck, Bristol Diabetes Drugs Linked to Pancreatitis Risk

Merck, Bristol Diabetes Drugs Linked to Pancreatitis Risk

Bloomberg

Merck's Dynamic Duo

Merck's Dynamic Duo

Motley Fool

What Will Type 2 Diabetes Treatments Look Like in 5 Years?

What Will Type 2 Diabetes Treatments Look Like in 5 Years?

Motley Fool

Merck ceases diabetes-cholesterol pill development

Merck ceases diabetes-cholesterol pill development

Marketwatch

Extending the Diabetes Dominance

Extending the Diabetes Dominance

Motley Fool

Merck: The Januvia Surge

Merck: The Januvia Surge

Seeking Alpha